Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet

Digestive Diseases and Sciences

Volumn 52, Issue 9, 2007, Pages 2380-2386

  Yalniz, Mehmet ^a   Bahçecioǧlu, I Halil ^a   Kuzu, Nalan ^a   Çelebi, Selman ^a   Ataseven, Hüseyin ^a   Üstündaǧ, Bilal ^a   Özercan, Ibrahim H ^a   Şahin, Kazim ^b  

^a FIRAT UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

Author keywords

Nonalcoholic steatohepatitis; Novel experimental model; Pentoxifylline

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MALONALDEHYDE; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CHEMISTRY; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT; STANDARD;

ANIMALS; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; FOLLOW-UP STUDIES; MALE; ORGAN SIZE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 34547843608     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9194-1     Document Type: Article

References (24)

1. Harrison SA, Kadakia S, Lang KA, Schenker S (2002) Nonalcoholic steatohepatitis: What we know in the new millennium. Am J Gastroenterol 97:2714-2724
2. Adams LA, Angulo P, Lindor KD (2005) Nonalcoholic fatty liver disease. CMAJ 172:899-905
3. Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with risk factors. Hepatology 12:1106-1110
4. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: Summary of An AASLD Single Topic Conference. Hepatology 37:1202-1219
5. Koteish A, Diehl AM (2002) Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16:679-690
6. Rosenbaum M, Leibel RL, Hirsch J (1997) Obesity. N Engl J Med 337:396-407
7. Reitman ML, Mason MM, Moitra J, Gavrilova O, Marcus-Samuels B, Eckhaus M, Vinson C (1999) Transgenic mice lacking white fat: Models for understanding human lipoatrophic diabetes. Ann NY Acad Sci 18:289-296
8. Ghoshal AK, Ahluwalia M, Farber E (1983) The rapid induction of liver cell death in rats fed a choline-deficient methionine low diet. Am J Pathol 113:309-314
9. 2 generation in liver mitochondria. Carcinogenesis 21:983-989
10. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM (2004) Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79:502-509
11. Day CP (2003) Pathogenesis of steatohepatitis. In Tözün N, Avşar E (eds) EASL 2003 38th Annual Meeting of the European Association for the Study of the Liver. Nonalcoholic fatty liver disease: From innocent bystander to progressive fibrosis and cirrhosis. President's premeeting syllabus. Istanbul, Turkey, 2003
12. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCharthy PJ, Crose RH, Cummings AG (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:148-149
13. Crespo J, Cayon A, FernandezGil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernadndez-Escalante JC, Pons-Romero F (2001) Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158-1163
14. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G (2004) Hepatic steatosis in obese patients: Clinical aspects and prognostic significance. Obes Rev 5:27-42
15. Zabel P, Schade FU, Schlaak M (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187:447-463
16. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd, Larrick J, Kunkel SL (1988) Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 155:1230-1236
17. Koppe SWP, Sahai A, Malladi P, Whitington PF, Green RM (2004) Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 41:592-598
18. Satoh K, Takamatsu S, Sakuta S, Mizuno S, Metoki H, Otakamatsu M (1981) Augmented malondialdehyde production by platelets from patients with cerebrovascular disorders. Jpn Circ J 45:1335-1341
19. Yagi K (1984) Assay for blood plasma or serums. Methods Enzymol 105:328-381
20. Ohkawa H, Ohishi N, Yagi K (1979) Assays for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358
21. Bahçecioǧlu IH, Yalniz M, Ataseven H, Bülbüller N, Keçec M, Demrdaǧ K, Özercan İ, Üstü ndaǧ B (2004) TNF-alpha and leptin in experimental liver fibrosis models induced by carbon tetrachloride and by common bile duct ligation. Cell Biochem Funct 22:359-363
22. Tilg D, Diehl AM (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343:1467-1476
23. Levi M, ten Cate H, Bauer KA, van der Pool T, Edgington TS, Büller HR, van Deventer SJH, Hack CE, Wouter ten Cate J, Rosenberg RD (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93:114120
24. Bhat VB, Madayastha KM (2001) Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun 288:1212-1217